-- Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
Avid Bioservices (NASDAQ: CDMO): Q2 2020 Earnings Snapshot
Categories
Biotechnology
Affimed (AFMD): Q3 2019 Earnings Snapshot
-- Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year. -- Revenues were EUR2.1
Where is Amarin (AMRN) headed after FDA panel favors Vascepa’s label expansion?
Biotech firm Amarin Corporation (NASDAQ: AMRN) had a positive start to the week, with the shares making sharp gains and hitting the
Bio-Path Holdings, Inc. (NASDAQ: BPTH): Q3 2019 Earnings Snapshot
-- Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019,
CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot
-- CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the
Amicus Therapeutics (FOLD): Q3 2019 Earnings Snapshot
-- Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected. -- Revenues grew
Obalon Therapeutics (NASDAQ: OBLN): Q3 2019 Earnings Snapshot
-- Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
MannKind (NASDAQ: MNKD): Q3 2019 Earnings Snapshot
-- MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected.
Cara Therapeutics’ (CARA) loss expands in Q3 on higher costs
Cara Therapeutics' (NASDAQ: CARA) loss widened in the third quarter of 2019, hurt by higher expenses. Cara Therapeutics posted a loss of
Viking Therapeutics (VKTX): Q3 2019 Earnings Snapshot
-- Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected. -- Net
Allergan (NYSE: AGN) Q3 loss widens but beats estimates
Allergan plc (NYSE: AGN) reported a wider loss in the third quarter of 2019 due to the divestitures, products that lost or
Intercept Pharmaceuticals posts Q3 miss, stock slips
Intercept Pharmaceuticals (NASDAQ: ICPT) on Tuesday reported third-quarter results that missed Wall Street expectations, but raised its guidance for the full year.
Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot
-- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected. --
Allergan (AGN) Q3 earnings preview: Patent issues, AbbVie deal in focus
After securing shareholders' approval for the takeover deal with AbbVie (ABBV), Allergan (NYSE: AGN) will be publishing its third-quarter results on November
Immunogen Inc (NASDAQ:IMGN) Q3 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q3 2019 earnings call dated Nov 1, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations
Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
Biogen (BIIB) earnings preview: Will stock bounce back after Q3 report?
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy
Pfenex shares shoot up on getting FDA approval for its osteoporosis drug
Shares of Pfenex (NYSE: PFNX) jumped over 15% in today's pre-market trading session as the clinical-stage biotech company received approval from the
Two zero-revenue biotech stocks debut in a shaky IPO market
The IPO market has recently been pretty unwelcoming, with some of the popular firms going dud right after their debut. Endeavor Group
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel.